Grifols S.A. Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 3, 2026 results vs estimates
Grifols S.A. Forecast
Grifols S.A. short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 28.9% a year, a typical one-standard-deviation range is 10.55–11.45 over a week, 10.08–11.92 over a month and 7.8159–14.18 over a year. (Signals as of 4 Nov 2026.)
Grifols S.A. Price Chart
Grifols S.A. Factors
YoY −17.0%
YoY +7.3%
YoY −3.0%
YoY +122.4%
YoY +121.8%
YoY −18.7%
YoY +20.5%
YoY +8.4%
YoY +3,297.4%
YoY +3,271.7%
YoY −6.2%
YoY −11.9%
YoY +17.1%
YoY +667.7%
YoY −25.0%
YoY +2.2%
Grifols S.A. fundamentals: income statement, balance sheet & cash flow
Grifols S.A. reported revenue of €7.52bn and net income of €401.9m in FY2025, the year ended 31 December 2025 — revenue up 4.3% and net income up 156.1% on the prior year. Free cash flow was €624.0m. These figures are as reported in the filings, not restated: 22 fiscal years and 65 quarters of history, back to December 2004.
| EUR millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 7,524.2 | 7,212.4 | 6,592.0 | 6,064.0 | 4,933.1 |
| Cost of revenue | 4,838.0 | 4,364.7 | 4,097.4 | 3,832.4 | 2,970.5 |
| Gross profit | 2,686.0 | 2,847.7 | 2,494.6 | 2,231.5 | 1,962.6 |
| Research & development | 426.0 | 384.0 | 330.6 | 361.1 | 354.9 |
| Operating income | 1,236.0 | 1,192.0 | 737.9 | 805.7 | 595.1 |
| EBITDA | 1,686.0 | 1,757.5 | 1,186.1 | 1,213.7 | 944.0 |
| Interest expense | 625.0 | 714.8 | 596.9 | 496.5 | 278.0 |
| Pre-tax income | 615.1 | 444.0 | 224.0 | 361.3 | 350.5 |
| Income tax | 114.6 | 231.2 | 43.3 | 90.1 | 85.1 |
| Net income | 401.9 | 156.9 | 59.3 | 208.3 | 265.3 |
Download Grifols S.A. fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.GRF.MC&statement=all&freq=a&format=csv&years=10
Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Grifols S.A.
Explore MacroFinance macro & markets research and analysis.
Grifols S.A. Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Grifols S.A.; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Grifols S.A.’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Grifols S.A. (Spain)
Grifols S.A. is a listed security in Spain. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Eagle Capital Growth Fund Inc
Frequently asked questions
What is Grifols S.A.?
What is the latest Grifols S.A. price?
Is Grifols S.A. in an uptrend?
How volatile is Grifols S.A.?
What factors affect Grifols S.A.?
Which trading strategies trade Grifols S.A.?
How are Grifols S.A. returns analysed?
Where can I download free Grifols S.A. historical data?
Free Grifols S.A. historical data (last 10 years)
Browse or instantly download the last 10 years of Grifols S.A. daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GRF.MC&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 10.905 |
| 2026-11-19 | 11.06 |
| 2026-11-18 | 11.41 |
| 2026-11-17 | 11.53 |
| 2026-11-16 | 11.605 |
| 2026-11-13 | 11.65 |
| 2026-11-12 | 11.66 |
| 2026-11-11 | 11.48 |
| 2026-11-10 | 11.375 |
| 2026-11-09 | 11.38 |
About this stock
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.